• News

Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitis

  • Practical Dermatology
  • New York, NY
  • (November 09, 2020)

Nearly one-third of participants in the 2 mg etrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment (vIGA), the FDA endpoint for Phase 3 registration, according to topline results from Arena’s Phase 2b ADVISE clinical trial evaluating etrasimod for the moderate-to-severe atopic dermatitis (AD).

Learn more